Tumor-induced sensitivity to apoptosis in T cells from patients with renal cell carcinoma: role of nuclear factor-kappaB suppression.

Antitumor immunity fails to adequately develop in many cancer patients, including those with renal cell carcinoma (RCC). A number of different mechanisms have been proposed to explain the immune dysfunction observed in cancer patient T cells. Here we show that T cells from RCC patients display increased sensitivity to apoptosis. Tumor-infiltrating lymphocytes (TILs) display the most profound sensitivity, because 10-15% of those cells are apoptotic when assessed by terminal deoxynucleotidyltransferase-mediated nick end labeling in situ, and the number of apoptotic TILs further increases after 24 h of culture. Peripheral blood T cells from RCC patients are not directly apoptotic, although T lymphocytes derived from 40% of those individuals undergo activation-induced cell death (AICD) upon in vitro stimulation with phorbol myristate acetate and ionomycin. This is in contrast to T cells from normal individuals, which are resistant to AICD. TILs and peripheral blood T cells from RCC patients also exhibit impaired activation of the transcription factor, nuclear factor (NF)-kappaB. Additional findings presented here indicate that the heightened sensitivity of patient T cells to apoptosis may be tumor induced, because supernatants from RCC explants sensitize, and in some instances directly induce, normal T cells to apoptosis. These same supernatants also inhibit NF-kappaB activation. RCC-derived gangliosides may represent one soluble tumor product capable of sensitizing T cells to apoptosis. Pretreatment with neuraminidase, but not proteinase K, abrogated the suppressive effects of tumor supernatants on both NF-kappaB activation and apoptosis. Additionally, gangliosides isolated from tumor supernatants not only inhibited NF-kappaB activation but also sensitized T cells to AICD. These findings demonstrate that tumor-derived soluble products, including gangliosides, may contribute to the immune dysfunction of T cells by altering their sensitivity to apoptosis.

[1]  N. Restifo.  Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape , 2000, Nature Medicine.

[2]  M. Lotze,et al.  Spontaneous apoptosis of CD8+ T lymphocytes in peripheral blood of patients with advanced melanoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  T. Whiteside,et al.  Tumor-induced apoptosis of T lymphocytes: elucidation of intracellular apoptotic events. , 2000, Blood.

[4]  T. Whiteside,et al.  Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. , 1999, Cancer research.

[5]  Ruixiang Li,et al.  Tumor gangliosides inhibit the tumor-specific immune response. , 1999, Journal of immunology.

[6]  N. Bander,et al.  Dead or dying: necrosis versus apoptosis in caspase-deficient human renal cell carcinoma. , 1999, Cancer research.

[7]  N. Tarantino,et al.  In Vivo Inhibition of NF-κB in T-Lineage Cells Leads to a Dramatic Decrease in Cell Proliferation and Cytokine Production and to Increased Cell Apoptosis in Response to Mitogenic Stimuli, But Not to Abnormal Thymopoiesis , 1999, The Journal of Immunology.

[8]  A. Hasegawa,et al.  Fas-independent cytotoxicity mediated by human CD4+ CTL directed against herpes simplex virus-infected cells. , 1999, Journal of immunology.

[9]  N. Bander,et al.  Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  A. Novick,et al.  Alterations in NFκB Activation in T Lymphocytes of Patients With Renal Cell Carcinoma , 1999 .

[11]  J. Finke,et al.  Where have all the T cells gone? Mechanisms of immune evasion by tumors. , 1999, Immunology today.

[12]  S. Rosenberg,et al.  Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. , 1999, Journal of immunology.

[13]  M. Lenardo,et al.  NF‐κB regulates Fas / APO‐1 / CD95‐ and TCR‐mediated apoptosis of T lymphocytes , 1999 .

[14]  W. Zong,et al.  The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-κB that blocks TNFα-induced apoptosis , 1999 .

[15]  C. Y. Wang,et al.  NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. , 1998, Science.

[16]  Z. Ao,et al.  IEX-1L, an Apoptosis Inhibitor Involved in NF-κB-Mediated Cell Survival , 1998 .

[17]  T. Whiteside,et al.  Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. , 1998, The Journal of clinical investigation.

[18]  M. Malim,et al.  Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[19]  C. Ohyama,et al.  Expression of Globo‐series Gangliosides in Human Renal Cell Carcinoma , 1997, Japanese journal of cancer research : Gann.

[20]  S. Nagata,et al.  Apoptosis by Death Factor , 1997, Cell.

[21]  D. Goeddel,et al.  The tumor necrosis factor receptor 2 signal transducers TRAF2 and c-IAP1 are components of the tumor necrosis factor receptor 1 signaling complex. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[22]  David Baltimore,et al.  An Essential Role for NF-κB in Preventing TNF-α-Induced Cell Death , 1996, Science.

[23]  G. Evan,et al.  A License to Kill , 1996, Cell.

[24]  K. Handa,et al.  Disialosyl galactosylgloboside as an adhesion molecule expressed on renal cell carcinoma and its relationship to metastatic potential. , 1996, Cancer research.

[25]  Mike Rothe,et al.  The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins , 1995, Cell.

[26]  F. Ramsdell,et al.  Fas and FasL in the homeostatic regulation of immune responses. , 1995, Immunology today.

[27]  E. Halapi,et al.  Lack of interleukin‐2 (IL‐2) expression and selective expression of IL‐10 mRNA in human renal cell carcinoma , 1995, International journal of cancer.

[28]  E. Tartour,et al.  Variable expression of CD3‐ζ chain in tumor‐infiltrating lymphocytes (TIL) derived from renal‐cell carcinoma: Relationship with til phenotype and function , 1995 .

[29]  T. Olencki,et al.  Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor‐infiltrating lymphocytes , 1995, International journal of cancer.

[30]  A. Pileri,et al.  T cells in multiple myeloma: is this a reliable population to count on as antitumor effector cells? , 1995, Leukemia & lymphoma.

[31]  S. Ju,et al.  Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation , 1995, Nature.

[32]  D. Morton,et al.  Aberrant expression of gangliosides in human renal cell carcinomas. , 1993, The Journal of urology.

[33]  E. Klein,et al.  T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. , 1993, Cancer research.

[34]  S. Miescher,et al.  Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors. , 1987, Journal of immunology.

[35]  K. Naito,et al.  [PPD, PHA and Su-PS skin tests in genitourinary malignancies]. , 1985, Hinyokika kiyo. Acta urologica Japonica.

[36]  S. Ladisch,et al.  A solvent partition method for microscale ganglioside purification. , 1985, Analytical biochemistry.

[37]  J. Finke,et al.  Inhibition of NF- kB Activity in Human T Lymphocytes Induces Caspase-Dependent Apoptosis Without Detectable Activation of Caspase-1 and -3 , 1999 .

[38]  S. Rosenberg,et al.  Human melanoma cells do not express Fas (Apo-1/CD95) ligand. , 1999, Cancer research.